Trulicity ® (dulaglutide)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Trulicity Summary of Product Characteristics (SmPC)

Trulicity® (dulaglutide): Switching From Another GLP-1 Receptor Agonist

No studies have been done on the effects of switching from another GLP-1 RA to dulaglutide.

Detailed Information

Dulaglutide is a GLP-1 RA indicated for once weekly dosing as an adjunct to diet and exercise for the treatment of adults with unsufficiently controlled T2DM.1 

No studies have been performed regarding switching to dulaglutide from another GLP-1 RA.

Physicians should follow their clinical judgment, taking into account the patient’s glycemic control, when deciding how to switch from one GLP-1 RA to another one. 

When switching a patient from another GLP-1 RA to dulaglutide, the prescribing information of the applicable GLP-1 RA and pharmacokinetic profile should be considered including

  • onset of action

  • duration of action

  • half-life

  • time to steady state, and 

  • missing dosing information.

Improvement in glycemic control with dulaglutide after the first administration is sustained throughout the once weekly dosing interval. The half-life of dulaglutide is approximately 5 days and steady-state concentrations of dulaglutide are achieved within 2 to 4 weeks.1

References

1. Trulicity [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Glossary

T2DM = type 2 diabetes mellitus

GLP-1 RA = glucagon-like peptide-1 receptor agonist

Date of Last Review: October 11, 2018

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question